Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 83.5% in June

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 254,500 shares, a growth of 83.5% from the May 31st total of 138,700 shares. Based on an average trading volume of 839,200 shares, the short-interest ratio is currently 0.3 days.

Astellas Pharma Price Performance

Shares of OTCMKTS ALPMY opened at $9.92 on Friday. The business’s 50 day moving average price is $9.75 and its 200 day moving average price is $10.67. The firm has a market cap of $17.95 billion, a P/E ratio of 141.71 and a beta of 0.39. Astellas Pharma has a 52 week low of $9.15 and a 52 week high of $15.90. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.31.

Astellas Pharma (OTCMKTS:ALPMY) last issued its earnings results on Thursday, April 25th. The company reported $0.11 EPS for the quarter. Astellas Pharma had a return on equity of 5.85% and a net margin of 1.20%. The firm had revenue of $2.79 billion for the quarter. On average, sell-side analysts expect that Astellas Pharma will post 0.36 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.